文献速递急性肾损伤

重组α1微球蛋白改善急性肾损伤幸存者预后

Recombinant alpha-1 microglobulin to improve outcomes in survivors of AKI.
PubMed 文献 · Nephrol Dial Transplant · 2026-01-01

急性肾损伤是大型手术后的常见严重并发症,机制涉及缺血再灌注损伤、补体激活、氧化应激和血红素毒性。临床前研究显示重组α1微球蛋白(A1M)在多种模型中有保护作用;RMC-035在1期试验中安全性良好、药代动力学呈剂量线性,心脏手术患者中显示肾小管应激与损伤生物标志物降低的早期信号;2期试验未达到降低术后72小时内AKI发生率的主要终点,但90天主要不良肾脏事件显著下降,主要由持续性肾功能不全发生率降低驱动。

要点

  • RMC-035在1期试验中安全性良好,药代动力学呈剂量线性。
  • 心脏手术患者1期研究显示肾小管应激与损伤生物标志物降低的早期信号。
  • 2期试验未达降低术后72小时内AKI发生率的主要终点,但90天主要不良肾脏事件显著下降。

核心结论

  • RMC-035在心脏手术患者2期试验中未达到降低术后72小时内AKI发生率的主要终点,但观察到90天主要不良肾脏事件显著下降,主要由持续性肾功能不全发生率降低驱动。
  • 正在进行的2b期研究旨在优化剂量策略并更好界定其长期肾脏保护疗效。

研究设计与样本

  • 综述性文章,汇总临床前研究、1期临床试验、心脏手术患者1期研究及2期试验的结果。

主要发现

  • 临床前研究中,A1M预处理显著减轻游离胎儿血红蛋白诱导的肾小球通透性改变,减少放射性肾损伤的氧化损伤标志物,并通过稳定线粒体功能在缺血再灌注损伤中提供保护。
  • 1期临床试验中,RMC-035显示安全性特征及可预测的剂量线性药代动力学。
  • 心脏手术患者1期研究中,RMC-035显示肾小管应激与损伤生物标志物降低的早期肾脏保护信号。
  • 心脏手术患者2期试验未达到降低术后72小时内AKI发生率的主要终点,但观察到90天主要不良肾脏事件显著下降,主要由持续性肾功能不全发生率降低驱动。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 2期试验未达到主要终点。
  • 2b期研究正在进行中,长期肾脏保护疗效尚未明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Acute kidney injury (AKI) is a serious and common complication among patients undergoing major surgery. The underlying pathophysiologic mechanism includes ischemia-reperfusion injury, complement activation, oxidative stress, and heme toxicity. Among potential preventive measures, recombinant alpha-1 microglobulin (A1M) emerged as a promising therapeutic candidate to mitigate kidney injury in high-risk clinical settings. Preclinical studies have shown its protective effect in different in vitro models such as cellular damage induced by radiation, proteases, and oxidative stress. In animal models, pretreatment with A1M significantly attenuated glomerular permeability changes induced by free fetal hemoglobin, reduced markers of oxidative injury in radiation-induced kidney damage, and conferred protection in ischemia-reperfusion injury by stabilizing mitochondrial function. These promising results led to the use of A1M in human patients. In Phase 1 clinical trials, RMC-035 demonstrated a safety profile with predictable, dose-linear pharmacokinetics. Moreover, in a Phase 1 study involving cardiac surgery patients, RMC-035 showed early signals of renal protection as indicated by reductions of renal tubular stress and injury biomarkers. Although a Phase 2 trial in cardiac surgery patients did not meet its primary endpoint of reducing the rate of AKI within 72 hours after surgery, a significant decline in major adverse kidney events at 90 days was observed that was mainly driven by a reduced rate of persistent renal dysfunction. An ongoing Phase 2b study aims to refine dosing strategies and better delineate its long-term renoprotective efficacy. Collectively, these studies seek to answer whether RMC-035 may improve kidney outcomes in settings characterized by oxidative and ischemia-reperfusion injury.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Marcello M, Schöne LM, Booke H, et al. Recombinant alpha-1 microglobulin to improve outcomes in survivors of AKI. Nephrol Dial Transplant. 2026. PMID: 41014235. doi:10.1093/ndt/gfaf194

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。